FindTrial
Sign In

Analysis for blood concentration and anti-drug antibody in anti-tumor antibody drugs

Analysis for blood concentration and anti-drug antibody in anti-tumor antibody drugs

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019946
Enrollment
Unknown
Registered
2018-12-09
Start date
2018-12-30
Completion date
Unknown
Last updated
2018-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Interventions

Case series:None

Sponsors

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18 to 80 years old; (2) Patients with a histologic or cytologic diagnosis of solid tumor; (3) Plan to receive Bevacizumab, Trastuzumab or Cetuximab which is determined by clinicians; (4) Life expectancy of at least 3 months.

Exclusion criteria

Exclusion criteria: 1. Have received Bevacizumab, Trastuzumab, Cetuximab or other biosimilars; 2. Have recieved or plan to recieve other monoclonal antibody drugs targeted to VEGR, HER2 and EGFR (including but not limit to Pertuzumab and Panitumumab)during this study; 3. History of drug abuse or alcoholism.

Design outcomes

Primary

MeasureTime frame
blood concentration;anti-drug antibody;—

Countries

China

Contacts

Public ContactNing Li

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

lining@cicams.ac.cn+86 15601395554

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026